Consonance-Hfw Acq Corp (SRZN)

$13.20 -0.54 (-3.93%)
Market Cap 117.77M
Revenue (ttm) 10.66M
Net Income (ttm) -63.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -596.25%
Debt to Equity Ratio 0.00
Volume 49,400
Avg Vol 52,346
Day's Range N/A - N/A
Shares Out 8.57M
Stochastic %K 60%
Beta 0.64
Analysts Strong Sell
Price Target $36.67

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat di...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 489 9000
Address:
171 Oyster Point Boulevard, Suite 400, South San Francisco, United States
Phaaisatroll
Phaaisatroll Nov. 22 at 12:12 AM
$SRZN really interested to hear about the progress of BI and Re-Vana regarding long acting drugs.
0 · Reply
Phaaisatroll
Phaaisatroll Nov. 21 at 1:21 PM
$SRZN we have a new 13G filing which shows Millennium Management now owns more than 5% of Surrozen. The last 13F filing of them showed ownership of 109.769 shares and now they own 564.847 shares. So another increase of tute ownership.
1 · Reply
Quantumup
Quantumup Nov. 20 at 8:41 PM
H.C. Wainwright reiterated $EYPT Buy/$23 $OCUL $FDMT $REGN KOD $SRZN Here is what HCW said in its note:
0 · Reply
Jw242
Jw242 Nov. 19 at 8:38 PM
$SRZN lord. I know I have sinned. But….
0 · Reply
raticals
raticals Nov. 19 at 7:08 PM
$SRZN bid is $13.16. That’s refreshing to see
1 · Reply
Jw242
Jw242 Nov. 18 at 9:42 AM
$SRZN column https://m.investing.com/news/insider-trading-news/column-group-boosts-surrozen-srzn-stake-with-399-million-purchase-93CH-4363997?ampMode=1 @Phaaisatroll @raticals 🤔
1 · Reply
Phaaisatroll
Phaaisatroll Nov. 16 at 1:34 PM
$SRZN with the current institutional holdings we have around 4.9 million shares in tute hands that only includes the 13F filings so some are missing in there. Not sure how much Column Group, Venrock, Perceptive Advisors and AI Biotechnology are holding right now but we have to add these and then we would know how much % are owned by tutes. Probably at least 90% of Surrozen is owned by them so only around 850000 shares for insiders and retail. https://fintel.io/so/us/srzn
2 · Reply
Phaaisatroll
Phaaisatroll Nov. 14 at 8:47 AM
$SRZN another company that's working on long acting VEGF drugs. Wondering if that technology would also work with our antibody drugs. https://www.optigobio.com/science
0 · Reply
raticals
raticals Nov. 12 at 2:39 PM
$SRZN sometimes you have to take one for the team and I did that a couple days ago.
1 · Reply
Phaaisatroll
Phaaisatroll Nov. 12 at 8:02 AM
$SRZN today is the Guggenheim conference and this is also soon:
0 · Reply
Latest News on SRZN
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2025, 5:01 PM EST - 9 days ago

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 4:05 PM EST - 14 days ago

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Surrozen to Present at Upcoming Healthcare Investor Conference

Nov 5, 2025, 4:05 PM EST - 16 days ago

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2025, 4:15 PM EDT - 2 months ago

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 8, 2025, 4:05 PM EDT - 3 months ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025, 8:30 AM EDT - 6 months ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 4:05 PM EDT - 7 months ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 31, 2025, 4:05 PM EDT - 8 months ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Mar 24, 2025, 9:00 AM EDT - 8 months ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 6, 2024, 4:30 PM EST - 1 year ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 6, 2024, 9:00 AM EST - 1 year ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Nov 4, 2024, 8:30 AM EST - 1 year ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 12, 2024, 8:30 AM EDT - 1 year ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 9, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Provides First Quarter 2024 Financial Results and Business Update

May 8, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 3, 2024, 8:40 AM EDT - 1 year ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Surrozen Provides Corporate Update on Clinical Programs

Jan 18, 2024, 8:30 AM EST - 2 years ago

Surrozen Provides Corporate Update on Clinical Programs

Surrozen Provides Third Quarter 2023 Financial Results

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Surrozen Provides Second Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Jun 5, 2023, 8:30 AM EDT - 2 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

May 10, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Apr 5, 2023, 8:30 AM EDT - 2 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Mar 25, 2023, 10:02 AM EDT - 2 years ago

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 22, 2023, 4:01 PM EDT - 2 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Mar 20, 2023, 4:30 PM EDT - 2 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 4:41 PM EST - 3 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:30 PM EST - 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 10, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Surrozen Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Jun 13, 2022, 8:00 AM EDT - 3 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 18, 2022, 8:00 AM EDT - 3 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 16, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

Surrozen Reports First Quarter 2022 Financial Results

May 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports First Quarter 2022 Financial Results

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 5, 2022, 8:00 AM EDT - 3 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 2, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 10, 2022, 8:00 AM EST - 4 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Jan 5, 2022, 8:00 AM EST - 4 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Phaaisatroll
Phaaisatroll Nov. 22 at 12:12 AM
$SRZN really interested to hear about the progress of BI and Re-Vana regarding long acting drugs.
0 · Reply
Phaaisatroll
Phaaisatroll Nov. 21 at 1:21 PM
$SRZN we have a new 13G filing which shows Millennium Management now owns more than 5% of Surrozen. The last 13F filing of them showed ownership of 109.769 shares and now they own 564.847 shares. So another increase of tute ownership.
1 · Reply
Quantumup
Quantumup Nov. 20 at 8:41 PM
H.C. Wainwright reiterated $EYPT Buy/$23 $OCUL $FDMT $REGN KOD $SRZN Here is what HCW said in its note:
0 · Reply
Jw242
Jw242 Nov. 19 at 8:38 PM
$SRZN lord. I know I have sinned. But….
0 · Reply
raticals
raticals Nov. 19 at 7:08 PM
$SRZN bid is $13.16. That’s refreshing to see
1 · Reply
Jw242
Jw242 Nov. 18 at 9:42 AM
$SRZN column https://m.investing.com/news/insider-trading-news/column-group-boosts-surrozen-srzn-stake-with-399-million-purchase-93CH-4363997?ampMode=1 @Phaaisatroll @raticals 🤔
1 · Reply
Phaaisatroll
Phaaisatroll Nov. 16 at 1:34 PM
$SRZN with the current institutional holdings we have around 4.9 million shares in tute hands that only includes the 13F filings so some are missing in there. Not sure how much Column Group, Venrock, Perceptive Advisors and AI Biotechnology are holding right now but we have to add these and then we would know how much % are owned by tutes. Probably at least 90% of Surrozen is owned by them so only around 850000 shares for insiders and retail. https://fintel.io/so/us/srzn
2 · Reply
Phaaisatroll
Phaaisatroll Nov. 14 at 8:47 AM
$SRZN another company that's working on long acting VEGF drugs. Wondering if that technology would also work with our antibody drugs. https://www.optigobio.com/science
0 · Reply
raticals
raticals Nov. 12 at 2:39 PM
$SRZN sometimes you have to take one for the team and I did that a couple days ago.
1 · Reply
Phaaisatroll
Phaaisatroll Nov. 12 at 8:02 AM
$SRZN today is the Guggenheim conference and this is also soon:
0 · Reply
raticals
raticals Nov. 11 at 9:02 PM
$MLTX quite the day for my biotechs 😀 $VKTX $SRZN $THQ
0 · Reply
raticals
raticals Nov. 11 at 7:44 PM
$SRZN your welcome
0 · Reply
Jw242
Jw242 Nov. 10 at 5:38 PM
$SRZN well this blows
1 · Reply
Phaaisatroll
Phaaisatroll Nov. 10 at 2:42 PM
$SRZN sublease extension with Nura Bio until May 2026. If Surrozen terminated their lease then it will end April 30, 2026. The 10Q didn't mention the termination option so we don't know if they terminated it or not. https://contracts.justia.com/companies/consonance-hfw-acquisition-corp-11397/contract/1346823/
1 · Reply
Phaaisatroll
Phaaisatroll Nov. 9 at 7:56 PM
$SRZN i hope they hired the new VP and the CFO to finish the job of selling the company. The VP Daniel Chao is going to a lot of conferences to show our drugs. Next is the Ophthalmology Innovation Source (OIS) conference on November 22. A lot of companies are presenting there also Re-Vana Therapeutics and Ripple Therapeutics. Both working on sustained release formulations. Ripple is working with Abbvie and Re-Vana with Boehringer Ingelheim. Here are the companies that are officially attending:
1 · Reply
Phaaisatroll
Phaaisatroll Nov. 9 at 9:53 AM
$SRZN the future in ophthalmology is sustained release drugs so it doesn't make much sense to start trials with our drugs how they are right now. They have to license sustained release technology from Re-Vana or another company or sell the company to somebody who already has such a technology(Boehringer Ingelheim, Roche, Regeneron).
0 · Reply
Phaaisatroll
Phaaisatroll Nov. 7 at 10:15 PM
$SRZN they published the quaterly report and hired a new CFO.
1 · Reply
Jw242
Jw242 Nov. 7 at 9:11 PM
$SRZN they gonna kill us now?
0 · Reply
Phaaisatroll
Phaaisatroll Nov. 7 at 8:54 AM
$SRZN Surrozen attended the Mary Tyler Moore Vision Initiative conference.
1 · Reply
Jw242
Jw242 Nov. 6 at 8:09 PM
$SRZN comedic
0 · Reply
Phaaisatroll
Phaaisatroll Nov. 6 at 1:24 PM
$SRZN at least the warrant traders have fun.
1 · Reply
raticals
raticals Nov. 5 at 9:00 PM
$SRZN could have been worse I guess
1 · Reply